Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189346 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL3159946 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL11429905 | 0.91 | MME (0.52) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL16199258 | 0.91 | MME (0.52) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL6624097 | 0.89 | CYP2C9 (0.45) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL6624100 | 0.89 | CYP2C9 (0.45) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL23894144 | 0.85 | PSMB5 (0.53) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL28310183 | 0.82 | MME (0.47) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL28310182 | 0.82 | MME (0.47) | ALDH1A1MAPTFAAHMMEACE | |
| SCHEMBL2269347 | 0.81 | FAAH (0.59) | ALDH1A1MAPTFAAHMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2019174279-A1 | 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2019-09-19 | — | — | WO | disclosed |
| EP-2941431-B1 | SUBSTITUTED MORPHINANS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9388162-B2 | Substituted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150175571-A1 | Substituted Morphinans and the Use Thereof | PURDUE PHARMA L.P. | 2015-06-25 | — | — | US | disclosed |
| CN-103243141-B | Method for preparing gamma-glutamyl small peptide compound by one-pot method | NANJING UNIVERSITY OF TECHNOLOGY | 2015-04-01 | — | — | CN | disclosed |
| US-8946255-B2 | Substituted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140187573-A1 | Substituted Morphinans and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120295823-A1 | OIL RELEASE WITH N-LAUROYL AMINO ACID-BASED COMPOUNDS | E.I DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120292022-A1 | COMPOSITION FOR IMPROVING OIL RECOVERY INCLUDING N-LAUROYL AMINO ACID-BASED COMPOUNDS AND MICROBES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-22 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | ALDH1A1 4455/4885MAPT 3626/4885FAAH 4783/4885 |
| US-20150175571-A1 | Substituted Morphinans and the Use Thereof | OPRL1, OPRM1, OPRK1 | ALDH1A1 763/4885MAPT 1659/4885FAAH 1905/4885 |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | ALDH1A1 588/4885MAPT 4/4885FAAH 1175/4885 |
| US-20140187573-A1 | Substituted Morphinans and the Use Thereof | OPRL1, OPRM1, OPRK1 | ALDH1A1 763/4885MAPT 1659/4885FAAH 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.